Jul 22, 2024 / 08:00AM GMT
Pablo Divasson del Fraile - Almirall SA - IR Contact Officer
Good morning, everyone. Thank you for joining us to review Almirall's H1 2024 financial results and business update. As usual, you can find the slides we are using today in the Investors section of our website at almirall.com.
Please move to slide number 2. Let me remind you that information presented in this call contains forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ.
With that, please advance to slide number 3. Presenting today, we have Carlos Gallardo, Chairman and Chief Executive Officer; Mike McClellan, Chief Financial Officer; and Karl Ziegelbauer, Chief Scientific Officer.
Carlos will start the H1 2024 highlights as well as the update on our biologics growth drivers that are crucial to our ambition of achieving leadership in medical dermatology. Karl will provide you with details on the progress of the pipeline. And Mike will review the financials before Carlos concludes the presentation and we will take your
Half Year 2024 Almirall SA Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)